Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Timms, Kirsten M ^a   Abkevich, Victor ^a   Hughes, Elisha ^a   Neff, Chris ^a   Reid, Julia ^a   Morris, Brian ^a   Kalva, Saritha ^a   Potter, Jennifer ^a   Tran, Thanh V ^a   Chen, Jian ^a   Iliev, Diana ^a   Sangale, Zaina ^a   Tikishvili, Eliso ^a   Perry, Michael ^a   Zharkikh, Andrey ^a   Gutin, Alexander ^a   Lanchbury, Jerry S ^a  

^a Myriad Genetic Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ALLELE; ARTICLE; BREAST CANCER; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; PROMOTER REGION; RECOMBINATION REPAIR; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER; ALLELIC IMBALANCE; BREAST TUMOR; DISORDERS OF DNA SYNTHESIS AND REPAIR; DNA METHYLATION; FEMALE; GENETICS; HOMOLOGOUS RECOMBINATION; METABOLISM; MUTATION; STATISTICAL MODEL; TUMOR SUPPRESSOR GENE;

ALLELIC IMBALANCE; BREAST NEOPLASMS; DNA METHYLATION; DNA REPAIR-DEFICIENCY DISORDERS; FEMALE; GENES, BRCA1; GENES, BRCA2; HOMOLOGOUS RECOMBINATION; HUMANS; LOGISTIC MODELS; LOSS OF HETEROZYGOSITY; MUTATION; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84924259541     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0475-x     Document Type: Article

References (15)

1. Fong PF, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. NEJM 2009, 361:123-134.
2. Byrski T, Gronwald J, Huzarski R, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S: Pathologic complete response rates in young women with BRCA1 -positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010, 28:375-379.
3. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Aksien LA: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482-1485.
4. Comen EA, Davids M, Kirchhoff T, Balistreri L, Hanse J, Kosarin K, Offit K, Robson ME: Prevalence of BRCA1 and BRCA2 mutations in Jewish women with triple negative breast cancer [abstract]. J Clin Oncol 2008, 26:22002.
5. Atchley DP, Albarracin ET, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GM, Arun BK: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008, 26:4282-4288.
6. Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakill I, Royer R, Li S, Harod SA: The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009, 9:86.
7. Hartman A-R, Kaldate RR, Sailer LM, Painter L, Grier C, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, Wenstrup RJ, Sandback JF: Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 2011, 118:2787-2795.
8. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury J, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB: Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011, 17:1082-1089.
9. Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Deng D, Narod SA, Xie Y: Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann Oncol 2013, 24:1498-1505.
10. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, Haverty PM, Peters BA, Wu TD, Amler LD, Chant J, Stokoe D, Lackner MR, Cavet G: Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009, 7:511-522.
11. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS: Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012, 107:1776-1782.
12. Birkbak NF, Wang ZC, Kim J-Y, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehard JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL: Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012, 2:366-375.
13. Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, Longy M, Houdayer C, Sastre-Garau X, Vincent-Salomon A, Stoppa-Lyonnet D, Stern M-H: Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012, 72:5454-5462.
14. Telli M, Jensen KC, Abkevich V, Hartman A-R, Vinayak S, Lanchbury J, Gutin A, Timms K, Ford JM: Homologous recombination deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple negative and BRCA1/2 mutation-associated breast cancer (BC). Cancer Res 2012, 72:PD09-04.
15. Beaudet AL, Tsui LC: A suggested nomenclature for designating mutations. Hum Mutat 1993, 2:245-248.